← Back to the boardHill
The House referred H.R. 10857, a bill amending the FD&C Act and Public Health Service Act on next-generation clinical development, to Energy and Commerce with a secondary referral to Ways and Means.
Why it’s here: A federal bill amending FDCA and PHSA to advance novel treatments and clinical development falls squarely within Biotechnology FDA regulation of novel therapies, and the referral to committees is a live legislative action.
Trace across the boardItem
Oct 21CongressCommittee on Energy and CommerceThe House referred H.R. 10857, a bill amending the FD&C Act and Public Health Service Act on next-generation clinical development, to Energy and Commerce with a secondary referral to Ways and Means.none specifiedH.R. 10857BiotechDetails2 linked
Coverage
1 outlets · first seen oct 21Connected
2 links- NewsSTAT+: Democrats take new step toward investigating Trump’s drug pricing dealsBoth involve House Energy and Commerce Committee, House Committee on Ways and Means
- HillH.R. 3521: Clinical Trial Modernization ActBoth involve House Energy and Commerce Committee, House Committee on Ways and Means
About
- House Energy and Commerce Committee
- House Committee on Ways and Means